Clinical Course, Molecular Remission, and Quality of Life under Pegylated Interferons in Patients with Polycythemia Vera and Essential Thrombocythemia – A Multicentric Long-Term Observation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039117

Enrollment

Registered

2026-03-16

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycythaemia vera and essential thrombocythemia

Interventions

Group 1: Retrospective analysis of patients with confirmed polycythemia vera or essential thrombocythemia receiving treatment with pegylated interferons in real-world

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed polycythemia vera or essential thrombocythemia based on the WHO/ICC 2022 criteria Treatment duration with ropeginterferon alfa-2b or peginterferon alfa-2a of at least more than 6 months

Exclusion criteria

Exclusion criteria: Treatment duration with ropeginterferon alfa-2b or peginterferon alfa-2a of less than 6 months

Design outcomes

Primary

Measure	Time frame
1. Complete hematologic response (CHR) 2. Reduction of MPN-specific allele burden 3. (Reduction in spleen size)	—

Secondary

Measure	Time frame
1. Tolerability of therapy (treatment-emergent adverse events) 2. Quality of life during therapy 3. Risk factors for lack of therapeutic response (e.g., neutrophil-to-lymphocyte ratio)	—

Countries

Germany

Contacts

Public ContactJosef Kim

Bundeswehrkrankenhaus Berlin - Klinik I

josefkim@bundeswehr.org030 2841 28205

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026